Time New York: Thu 24 May 13:46 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Zoetis (ZTS) Q4 Earnings & Revenues Surpass Estimates

Zacks

Florham Park, NJ-based Zoetis Inc. ZTS is one of the leading global animal health companies focused on the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company came into existence following Pfizer’s decision to spin off its animal health business in 2013.

Zoetis’ diversified portfolio of products for livestock and companion animals should continue to drive top-line growth at the company. The company’s top line should benefit from the addition of products acquired from Abbott Laboratories (February 2015), Pharma (November 2015), Nexvet (July 2017) as well as from the performance of Apoquel and other key brands. In this scenario, investor focus remains on top-and bottom-line numbers.

Zoetis’ track record has been impressive with the company beating earnings estimates consistently. In fact, Zoetis’ earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 4.51%.

Currently, Zoetis has a Zacks Rank #2 (Buy),but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:


Earnings In-line: Zoetis reported earnings per share of 69 cents beating the Zacks Consensus Estimate of 66 cents in fourth-quarter of 2017.

Revenues Beat: Zoetis posted revenues of $1.5 billion surpassing the Zacks consensus estimate of $1.40 billion.

Key Stats: During the fourth quarter, Zoetis continued to expand the availability of its oral flea and tick medication, Simparica into new markets, with additional approvals in Chile, Panama, the Philippines and Switzerland. Simparica also received approval in the European Union for the treatment of two additional types of skin mites.In the United States, the company enhanced its medicated feed additives portfolio with an expanded claim for Lincomix (lincomycin hydrochloride), a popular feed medication.

2018 Outlook: Zoetis provided its outlook for 2018. In 2018, the company expects adjusted earnings in the range of $2.96 to $3.10 per share on revenues of $5.675 billion and $5.800 billion. The Zacks Consensus Estimate for earnings is $2.94 per share on revenues of $5.64 billion.

Share Price Impact: Shares of the company were up 0.7% in-pre-market trading.

Check back later for our full write up on this ZTS earnings report later!

Zoetis Inc. Price and EPS Surprise

Zoetis Inc. Price and EPS Surprise | Zoetis Inc. Quote

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now.

Click here >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.

Get AutoBlogged